Development and Evaluation of High Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
Preprint
- 1 July 2025
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
TRIM24 is an epigenetic transcriptional coregulator that ‘reads’ KMe3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off-target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3-mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide-drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate (koff), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.Keywords
All Related Versions
- Version 1, 2025-07-01, ChemRxiv
- Published version: Chemistry – A European Journal, 31 (72), e03011.
Funding Information
- Biotechnology and Biological Sciences Research Council (BB/T008784/1)
This publication has 36 references indexed in Scilit:
- Discovery and optimization of novel N-benzyl-3,6-dimethylbenzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activitiesBioorganic Chemistry, 2020
- Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target ValidationAngewandte Chemie International Edition, 2019
- TRIM24 Is an Oncogenic Transcriptional Activator in Prostate CancerCancer Cell, 2016
- Towards understanding methyllysine readoutBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2014
- Druggability of methyl-lysine binding sitesJournal of Computer-Aided Molecular Design, 2011
- A Poised Chromatin Platform for TGF-β Access to Master RegulatorsCell, 2011
- TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- The Site-Specific Installation of Methyl-Lysine Analogs into Recombinant HistonesCell, 2007
- A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors.The EMBO Journal, 1996
- Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1.The EMBO Journal, 1996